USE OF A COMBINATION OF АVASTIN AND LOW-DOSE INTERFERON- α IN THE FIRST-LINE TREATMENT OF METASTATIC RENAL-CELL CANCER

Background. The registered AVOREN Phase III trial demonstrated the efficacy of a combination of bevacizumab and interferon-α (IFN-α) as first-line targeted therapy in patients with metastatic renal-cell cancer (mRCC). The median progression-free survival (PFS) was significantly higher in the bevaciz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: A. S. Kalpinsky, B. Ya. Alekseyev, A. D. Kaprin
Formato: Artigo
Idioma:Russo
Publicado em: ABV-press 2013-09-01
Colecção:Onkourologiâ
Assuntos:
metastatic renal-cell cancer
targeted therapy
angiogenesis inhibitors
bevacizumab
avastin
Acesso em linha:https://oncourology.abvpress.ru/oncur/article/view/114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados